The long‐term antiproliferative effects of HR inhibition combined with ferroptosis suggest that pharmacological inhibition of HR and ferroptosis defenders or administration of ferroptosis inducers to HR‐deficient cancers could be an effective anticancer strategy. Here, HR is linked to cancer.